Old versus new: weighing the evidence between the firstand second-generation antipsychotics

被引:22
|
作者
Davis, JM [1 ]
Chen, N [1 ]
机构
[1] Univ Illinois, Univ Maryland Psychiat Res Ctr, Dept Psychiat, Chicago, IL 60680 USA
关键词
antipsychotics; meta-analysis; efficacy; dose;
D O I
10.1016/j.eurpsy.2004.11.002
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
In our opinion the best guide to prescribing antipsychotics is the clinician's experience with his patients and in particular the patient being treated. If treatment works. stick with it. We feel it is also important for the clinician to consider the evidence front well-controlled double-blind random-assignment studies because in "evidence-based medicine," biases both known and unknown are controlled by blinding, and randomization. The purpose of this paper is to summarize and discuss the evidence on efficacy. Choice of antipsychotic. in our opinion. is probably the most important decision that the clinician makes for the psychotic patient. This involves the choice of drug. its dose. balancing efficacy, side-effects and cost. (C) 2004 Published by Elsevier SAS.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 50 条
  • [31] "Salami Slicing" in Pooled Analyses of Second-Generation Antipsychotics for the Treatment of Depression
    Spielmans, Glen I.
    Olson, Shaundra
    Keicher, Ruth M.
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2017, 86 (03) : 171 - 172
  • [32] Second-generation antipsychotics in major depressive disorder: update and clinical perspective
    Chen, Jun
    Gao, Keming
    Kemp, David E.
    CURRENT OPINION IN PSYCHIATRY, 2011, 24 (01) : 10 - 17
  • [33] Second-generation antipsychotics: A review of recently approved agents and drugs in the pipeline
    Holmes, Jamie C.
    Zacher, Jennifer L.
    FORMULARY, 2012, 47 (03) : 106 - +
  • [34] Adipose tissue as a target for second-generation (atypical) antipsychotics: A molecular view
    Ferreira, Vitor
    Grajales, Diana
    Valverde, Angela M.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2020, 1865 (02):
  • [35] Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
    Grajales, Diana
    Ferreira, Vitor
    Valverde, Angela M.
    CELLS, 2019, 8 (11)
  • [36] Subjective Versus Objective Weight Gain During Acute Treatment With Second-Generation Antipsychotics in Schizophrenia and Bipolar Disorder
    Gao, Keming
    Fang, Fang
    Wang, Zuowei
    Calabrese, Joseph R.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 36 (06) : 637 - 642
  • [37] DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder
    Burghardt, Kyle J.
    Goodrich, Jacyln M.
    Dolinoy, Dana C.
    Ellingrod, Vicki L.
    EPIGENOMICS, 2015, 7 (03) : 343 - 352
  • [38] Is obstructive sleep apnea the missing link between metabolic syndrome and second-generation antipsychotics: Preliminary study
    Rohatgi, Rupali
    Gupta, Ravi
    Ray, Rajat
    Kalra, Vinita
    INDIAN JOURNAL OF PSYCHIATRY, 2018, 60 (04) : 478 - 484
  • [39] Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients
    Takekita, Yoshiteru
    Fabbri, Chiara
    Kato, Masaki
    Nonen, Shinpei
    Sakai, Shiho
    Sunada, Naotaka
    Koshikawa, Yosuke
    Wakeno, Masataka
    Okugawa, Gaku
    Kinoshita, Toshihiko
    Serretti, Alessandro
    NEUROPSYCHOBIOLOGY, 2015, 72 (02) : 118 - 125
  • [40] Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia
    Addington, Donald E.
    Mohamed, Somaia
    Rosenheck, Robert A.
    Davis, Sonia M.
    Stroup, Thomas Scott
    McEvoy, Joseph P.
    Swartz, Marvin S.
    Lieberman, Jeffrey A.
    JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (01) : 75 - 80